Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.54 [0.07, 36.11]1 study · 60 participantsLow